CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

STATUS

Recruiting
participants needed

9
sponsor

Stergios Zacharoulis

Send

Updated on 19 February 2024

See if I qualify

anesthesia

anticonvulsants

platelet count

serum pregnancy test

neutrophil count

karnofsky performance status

thromboplastin

epilepsy

seizures

acute infection

dipg

coagulation disorder

diffuse intrinsic pontine glioma

pediatric

glioma

side effects of drugs

Summary

The blood brain barrier (BBB) prevents some drugs from successfully reaching the target source. Convection-Enhanced Delivery (CED) is a method of direct infusion of drugs under controlled pressure to the tumor that may reduce systemic side effects of drugs in the patient.

The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.

Description

Diffuse midline gliomas (DMGs), constitute 10% of all pediatric central nervous system (CNS) tumors. Subjects with Diffuse Intrinsic Pontine Gliomas (DIPG) have a poor prognosis with a median survival that is usually reported to be 9 months, and nearly 90% of children die within 18 months from diagnosis. The mainstay of treatment is radiation to the primary tumor site. Surgical resection does not influence outcome and is often not feasible in this part of the central nervous system.

Many promising drugs for central nervous system (CNS) disorders have failed to attain clinical success due to an intact blood brain barrier (BBB), limiting their access form the systemic circulation into the brain. Systemic administration of high doses may increase delivery to the brain, but this approach risks significant side effects and systemic toxicities. Direct delivery of the drugs to the brain by injection into the parenchyma bypasses the BBB, however, drug distribution form the site of injection tends to be limited. The convection-enhanced delivery (CED) of drugs describes the infusion of drugs under controlled pressure to the brain parenchyma via targeted microcatheter. This technique facilitates and deliver higher drug concentrations in brain tissue or tumor. The BBB can now operate to retain drug and to significantly reduce systemic side effects. In addition, the fact that panobinostat seems to be most efficacious clinically available drug against DIPG cells.

Details

Condition	Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma
Age	3years - 18years
Treatment	Infusate with MTX110 and gadolinium, Convection-Enhanced Delivery (CED)
Clinical Study Identifier	NCT04264143
Sponsor	Stergios Zacharoulis
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Aged more than 3 years up to the 18th birthday
	Radiological diagnosis of DIPG with tumor confined to the region of the pons or
	thalami without cystic changes or hematoma obstructing the planned catheter trajectories
	Radiological diagnosis of thalamic gliomas confined to bilateral thalami without cystic changes or hematoma obstructing the planned catheter trajectories
	Radiological features of DIPG: intrinsic, pontine based infiltrative lesion; hypointense in T1 weighted images (T1WIs) and hyperintense in T2 sequences, with mass effect on the adjacent structures and occupying at least 50% of the pons
	No prior therapy is allowed other than involved field radiotherapy (54Gy) and cerebrospinal fluid (CSF) diversion for hydrocephalus, including endoscopic third ventriculostomy (ETV) or a ventriculo-peritoneal shunt. No concomitant medicine or therapies for treatment are permitted while the patient is enrolled in this study
	Karnofsky performance status or Lansky play score of 70 assessed at diagnosis
	Total bilirubin: within normal institutional limits
	Aspartate Aminotransferase (AST)(SGOT)/Alanine Aminotransferase (ALT)(SGPT): 2.5 institutional upper limit of normal (ULN)
	Creatinine: within normal institutional limits
	Creatinine clearance: 60 mL/min/1.73m2 for patients with creatinine levels above institutional normal
	Absolute neutrophil count: 1,500/L
	Platelet count: 100,000/L - no transfusion within 7 days
	Hemoglobin level: 10g/dL - no transfusion within 7 days
	Partial Thromboplastin Time (PT) and activated partial thromboplastin time (APTT): within normal institutional limits
	No documented current bleeding disorder
	No medical condition that would preclude general anesthesia
	No severe acute infection or unexplained febrile illness
	Not pregnant or nursing - negative serum pregnancy test if appropriate within 7 days of study entry (adequate contraceptive methods for females and males required)
	No documented allergy to compounds of similar chemical or biologic composition to MTX110 or gadolinium compounds
	Subjects with a history of seizures/epilepsy should be on anticonvulsant medication prior to the first operative procedure on study, with serum levels within a therapeutic range
	Subjects must be able to undergo MR-imaging with gadolinium-based contrast administration (e.g. no ferrous-containing implants, no pacemakers, etc.)
	All subjects or their legal guardians must sign a document of informed consent indicating their understanding of the investigational nature and the potential risks associated with this study. When appropriate, pediatric subjects will be included in all discussions in order to obtain verbal and written assent
Exclusion Criteria
	Radiological evidence of distant disease outside the pons or thalami
	Radiological evidence of metastatic disease within the central nervous system (CNS) at diagnosis
	Subjects with an uncorrectable bleeding disorder
	Subjects with multifocal or leptomeningeal disease beyond the pons or the thalami
	Subjects with signs of impending herniation or an acute intratumoral hemorrhage
	Subjects that have received or are on concurrent chemotherapy or biologic therapy for the treatment of their tumor
	Subjects who are pregnant or breastfeeding
	Previous experimental or trial-based therapy
	Patients who are known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C positive. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with MTX110
	Patients with systemic diseases which may be associated with unacceptable anesthetic/operative risk

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

karnofsky performance status

diffuse intrinsic pontine glioma

pediatric

glioma

side effects of drugs

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas